Gastroenterology

Back to articles

COX-2 Inhibitors: Cardiac Concerns Added, GI Warnings Remain

KEY POINT

As Merck and Pharmacia continue to compete for the $3.67 billion COX-2 inhibitor market, two large, company- sponsored studies have exposed new safety questions about both companies’ medications. First, the studies suggest that the gastroprotective effects of the COX-2 inhibitors may not be as significant as once thought. Second, they raise the possibility that the agents put patients at risk for cardiovascular adverse events.

SOURCES

FDA Arthritis Advisory Committee. Meeting documents, February 7–8, 2001.

Anonymous. Various articles. FD&C Reports: The Pink Sheet. February 12, 2001:3–8.

Statement of Sidney M. Wolfe, MD, and Larry Sasich, PharmD, MPH, of the Public Citizen Health Research Group, before FDA’s Arthritis Advisory Committee. February 7–8, 2001.

Otto A. Crashing the Celebrex celebration. Washington Post. January 2, 2001:T6.